A higher pulmonary vascular resistance index during exercise, but not at rest, predicts poor clinical outcomes in adults with Fontan circulation, highlighting the value of invasive exercise testing.

Of the thousands of children born each year with congenital heart defects, a small cohort have severe malformations of their cardiac chambers leading to a single ventricle physiology. The current ...

SEOUL, South Korea, June 30, 2020 /PRNewswire/ -- Mezzion Pharma Co. Ltd. (140410.KQ), announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) ...

CCHMC is building a new learning network to assess long-term complications of a procedure for people born with a variety of congenital heart defects. A doctor at Cincinnati Children’s Hospital Medical ...

PHILADELPHIA — In a phase 3 study, the phosphodiesterase-5 (PDE-5) inhibitor udenafil (Mezzion Pharma) did not improve the primary end point of oxygen consumption at peak exercise, but was associated ...

Patients who have had surgery to create a Fontan circulation show changes in their genetic code, which may provide a new treatment opportunity to reduce premature aging. The procedure is used to treat ...

CHICAGO -- Each child had already undergone at least three open-heart surgeries. They'd endured countless hours in doctors' offices and hospitals after being born with a serious heart condition. But ...

A multi-center study has identified critical risk factors that increase the likelihood of death in children with a heart defect who are awaiting or have recently undergone heart transplantation, ...

Mezzion Pharmaceuticals, Inc. (Mezzion), a late-stage rare disease biopharmaceutical company developing the first potential ...

SEOUL, South Korea, Aug. 12, 2025 /PRNewswire/ -- A newly published post-hoc analysis of the landmark FUEL (Fontan Udenafil Exercise Longitudinal) Trial demonstrates that udenafil, a PDE5 inhibitor, ...